Healthy Ventures

Healthy Ventures Research Investment Thesis Healthy Ventures is a specialized, thesis-driven healthcare venture capital firm focused on early-stage companies solving complex infrastructure and go-to-market challenges in healthcare. Founded with a mission to unlock the full potential of healthcare through technology, the firm backs founders building solutions in healthcare infrastructure—including middleware, payments, clinical trials management, and data architecture—while providing hands-on commercialization support. The firm's core belief is that solving healthcare's biggest challenges requires understanding both healthcare AND broader markets. They emphasize that the best product doesn't win—the best distribution wins. This conviction has shaped their investment approach and platform services. Investment Focus & Sector Healthy Ventures invests in early-stage health-tech companies solving complex, often overlooked problems at the intersection of healthcare and technology. Their investment focus includes: Core Investment Areas: Healthcare Infrastructure & Middleware (data integration, governance) Healthcare Payments & Patient Financial (claims processing, patient payments, billing) Clinical Trials Infrastructure (electronic data capture, patient recruitment, protocol management) Healthcare Data Architecture (data cleaning, analytics, insights generation) Healthcare Operations & Workflow (provider operations, specialty care coordination, pharmacy analytics) Payer-Provider Alignment Tools (value-based care infrastructure, contract adjudication) Healthcare Cybersecurity (especially for SMBs) Digital Clinical Solutions (telemedicine, chronic disease management, behavioral health) Life Sciences Tech (biopharma compliance, clinical research, genomics) They explicitly do NOT invest in : FDA-approved drugs and devices, pure services businesses, consumer wellness and health, or AAA healthcare business models. Stage Focus Healthy Ventures is a seed-stage lead investor , with increasing Series A participation: Seed: $1-3M typical entry check size (primary focus) Series A: Occasional lead or syndicate participation Board Participation: Double-digit ownership typical, with board seats The firm operates with conviction-driven investing—they prefer to lead rounds and are comfortable being the only investors believing in a company at the time. Check Size Entry checks: $1-3M (typical for seed rounds) Minimum: $500K observed in portfolio Maximum: $2M observed as typical seed size They provide follow-on reserves and maintain board seats for portfolio oversight. Investment Approach Healthy Ventures differentiates itself through a structured, hands-on partnership model: Conviction Over Consensus They invest when they've done the work to believe a solution has a "real, unfair shot" at market impact. They're comfortable being alone in this belief and leading rounds without consensus from other investors. Go-To-Market as Core Competency Unlike most VCs, Healthy Ventures operates a dedicated GTM platform staffed with go-to-market operating partners who work directly with founders on: Market targeting and segmentation Product positioning and value proposition Marketing content creation and narrative Demand generation and conversion optimization They explicitly state: "We are the only early-stage health-tech VC that delivers core GTM resources for founders." This addresses what they see as the biggest gap in health-tech: founders can build great products but struggle with repeatable, scalable sales and marketing. Founder-Led Learning Culture They seek founders powered by "we can learn" mentality, not "we already know." They value technical founders with deep healthcare domain expertise who are willing to evolve their approach. Complex Problem Focus They specifically seek solutions addressing difficult, unglamorous problems in healthcare infrastructure—not sexy household names, but solutions removing friction in how healthcare operates. Recent Portfolio Activity Based on current portfolio page research (as of February 2026), Healthy Ventures has deployed at least 40+ companies across their fund(s). Notable recent investments and exits visible on their website: Recent Acquisitions/Exits: OneCodex (acquired by Invitae/LabCorp) - microbial genomics PokitDok/Change (acquired by Change Healthcare) - healthcare APIs and blockchain WootCloud (acquired by Netskope) - healthcare cybersecurity/device detection Whiz.ai (acquired by IQVIA) - life sciences analytics Sprockets (acquired by Humanly) - talent matching for healthcare SubjectWell (acquired by IQVIA) - clinical trial patient recruitment HealthiPass (acquired by Sphere) - patient payment solutions HealthCrowd (acquired by mPulse) - patient engagement Decent (merged with Nice Healthcare) - health insurance Active Portfolio (Partial List): Akido Labs - healthcare IT integration Anagram - out-of-network claims reimbursement Arbital Health - value-based care contracts Carta Healthcare - healthcare data architecture ClinCapture - clinical trial data capture Concert Health - primary care behavioral health outsourcing CornerstoneAI - healthcare data cleaning and insights DaylightRx - pharmacy analytics and optimization EasyHealth/Joineasy - Medicare benefits navigation Goodpath - chronic disease management AI HealthiPass - patient payment processing Inbox Health - patient payment infrastructure Lamar Health - prior authorization AI LighthouseAI - supply chain compliance for life sciences Macro Trials - distributed clinical trials infrastructure Season Health - food-as-medicine via insurance channels StudyOS - clinical trial protocol deviation monitoring SubjectWell - clinical trial patient matching Zeguro - SMB cybersecurity insurance Team & Advisors Investment Team: Enmi Kendall, General Partner: 20+ years in early-stage venture investing, passionate about healthcare transformation Madeline Bradley, Vice President: Focuses on opportunity identification and portfolio support Rosalind Chu, VP of Platform & Operations: 10+ years collaborating with entrepreneurs, strong background in business ops, critical path analysis, and operations infrastructure High-Profile Advisors: Stephen Bewley (ex-COO InStride Health, ex-CEO AbleTo/Optum) - healthcare operations and payer distribution MaryJo Zaborowski (ex-CIO Cold Spring Harbor Lab, ex-Parexel, ex-Merck/Janssen) - biopharma data expert Hill Ferguson (founder Doctors-on-Demand) - telemedicine pioneer and payer reimbursement expert Kevin Leininger (ex-CEO IntegriChain) - biopharma commercialization Hugh Levaux (founder Protocol First/Flatiron, ex-Medidata, ex-Quintiles/IQVIA) - clinical research tech Hari Sundram, M.D. (founder Predilytics, Verikai, Radion Health) - insuretech and predictive data Chris Sacca (founder Lowercase Capital, Lowercarbon Capital) - trend spotting and strategic vision Liam Donohue (co-founder .406 Ventures) - health tech market insights and team building Lead Tendency Leads seed rounds - They explicitly state "We typically lead Seed rounds" in FAQs. For Series A, they participate in both lead and syndicate positions, though with higher selectivity. Decision Process Based on website content, decision process appears to be partnership-based with conviction-driven investment: Emphasis on "investment with conviction, not consensus" Board seat expectations indicate meaningful post-investment engagement Dedicated GTM team involvement suggests structured decision and support process Lead investor positioning suggests relatively fast decision timelines Decision timeline appears to be moderate (2-4 weeks) based on their commitment to conviction-driven investing and hands-on support model. Warm Introductions While not explicitly stated, their emphasis on conviction-driven investing and specific sector focus suggests warm introductions are strongly preferred to ensure alignment with their thesis. Cold outreach is less likely to resonate. Geographic Focus Primary: San Francisco Bay Area (headquarters based) Secondary: Likely US-focused with portfolio concentrated in US geographies Stage: All geographies with strong healthcare presence and regulatory infrastructure Typical Post-Investment Involvement Board Participation: Yes - typical for portfolio companies (double-digit ownership and board seats) Operational Support: High engagement through dedicated GTM platform, operating partner involvement, founder workshops, access to templates/tools, formal coaching, and advisor network access Follow-On Reserves: Maintained for follow-on investments in successful portfolio companies Founder Preferences Healthy Ventures seeks founders with: Deep healthcare domain expertise - Understanding clinical workflows, healthcare operations, and regulatory landscape Technical sophistication - Ability to solve difficult data and infrastructure problems Product-focused founding teams - Building product-based businesses, not services Growth mindset - "We can learn" mentality, not "we already know" Distribution awareness - Understanding that product alone doesn't win; distribution and go-to-market matter Conviction and clarity - Ability to articulate why their solution has an "unfair shot" at scale Values & Culture Healthy Ventures explicitly articulates their values: Asymmetric Focus: Great opportunities are often the most overlooked Self-Awareness: Partnership with those who complement strengths Curiosity and Rigor: Genuine desire to understand, backed by rigorous work Agency: Owner mentality focused on changing outcomes, not observing them They emphasize "tell it like it is" approach, hands-on involvement, and willingness to provide candid feedback. Competitive Positioning Healthy Ventures' key differentiators: Only early-stage health-tech VC with dedicated GTM resources - Structured go-to-market platform Conviction-driven investing - Comfortable leading alone Healthcare domain expertise - Deep advisory board and team healthcare knowledge Founder-first mentality - 20+ years of founder support experience Thesis-driven focus - Clear about investment scope and anti-thesis Recent Activity & Fund Status Based on portfolio page showing 40+ companies and active website updates, Healthy Ventures appears to be actively deploying from current fund(s). The firm continues to invest in seed rounds and maintain portfolio engagement. No explicit fund size or vintage year mentioned on website, but the breadth of portfolio and recent activity suggest an active, well-deployed fund. Anti-Thesis Healthy Ventures explicitly does NOT invest in: FDA-approved drugs and devices Pure services businesses Consumer wellness and health Companies without clear product differentiation Non-product founders or teams They focus on infrastructure and B2B/B2B2C healthcare solutions, not direct consumer health apps.